.Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX08_Reslizumab.Reslizumab .Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX08_Reslizumab.Reslizumab| name: | Reslizumab | |
| ATC code: | R03DX08 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 3.0 | mg |
| volume of distribution: | 5.0 | L |
| clearance: | 0.19 | L/h |
| other parameters in model implementation | ||
Reslizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), used primarily for the treatment of severe eosinophilic asthma as an add-on maintenance therapy in adults. It is approved by FDA and EMA for this indication.
Pharmacokinetic parameters in adults with eosinophilic asthma following intravenous administration.
Passarell, J, et al., & Bond, M (2020). Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing. Journal of clinical pharmacology 60(8) 1039–1050. DOI:10.1002/jcph.1609 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32333684